Trial reportLeukemia2022
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
2 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase IILetterMulticenter Study
In one paragraph
Trial report in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Phase II, Multicenter, Open-label Study Evaluating iNduction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma paTients
GEM21menos65. A Phase III Trial for NDMM Patients Who Are Candidates for ASCT Comparing Extended VRD Plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.Nature medicine · 2026Trial
- Trial
- Counting the CHIPs: The High-Stakes Role of Clonal Hematopoiesis in Multiple Myeloma.Biomedicines · 2026Review
- Article
- Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial.Cardio-oncology (London, England) · 2025Article
- Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.HemaSphere · 2025Review
- Review
- Article
- Presentation of extramedullary myeloma manifestations on B-mode (B-US) and contrast-enhanced ultrasound (CEUS).Journal of ultrasonography · 2025Article
- Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study).Frontiers in oncology · 2025Article
- Article
- Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.Blood cancer journal · 2024Article
- Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.BMC cancer · 2024Article
- Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients.Life (Basel, Switzerland) · 2024Review
- Targeted immunotherapy: harnessing the immune system to battle multiple myeloma.Cell death discovery · 2024Review
- The characteristics of patients with multiple myeloma surviving over 10 years.Frontiers in oncology · 2024Article
- Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report.Frontiers in immunology · 2024Article
- Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.Cancer research communications · 2023Article
- A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 15 institutions in 1 country.
Lisa B LeypoldtDepartment of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-9248-588X
Britta BesemerDepartment of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany.
Anne Marie AsemissenDepartment of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mathias HänelDepartment of Hematology, Oncology and Bone Marrow Transplantation, Klinikum Chemnitz, Chemnitz, Germany.
Igor Wolfgang BlauDepartment of Internal Medicine, Charité University Medicine Berlin, Berlin, Germany.
Martin GörnerDepartment of Hematology, Oncology and Palliative Care, Klinikum Bielefeld Mitte, Bielefeld, Germany.
Yon-Dschun KoDepartment of Internal Medicine, Hematology and Oncology, Johanniter Krankenhaus Bonn, Bonn, Germany.
Hans Christian ReinhardtDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, German Cancer Consortium (DKTK partner site Essen), Essen, Germany.
Peter StaibDepartment of Hematology and Oncology, St. Antonius Hospital Eschweiler, Eschweiler, Germany.
Christoph MannDepartment of Hematology, Oncology and Immunology, University Hospital of Gießen and Marburg, Marburg, Germany.
Raphael LutzUniversity Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Markus MunderDepartment of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.
Ullrich GraevenDepartment of Hematology, Oncology and Gastroenterology, Maria Hilf Kliniken, Mönchengladbach, Germany.ORCID http://orcid.org/0000-0001-6082-7710
Rudolf PecenyDepartment of Oncology, Hematology and Stem Cell Transplantation, Klinikum Osnabrück, Osnabrück, Germany.
Hans SalwenderAsklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany.ORCID http://orcid.org/0000-0001-7803-0814
Anna JauchInstitute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
Manola ZagoCenter for Clinical Trials, University Hospital of Tuebingen, Tuebingen, Germany.
Axel BennerDivision of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7238-6956
Diana TichyDivision of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
Carsten BokemeyerDepartment of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hartmut GoldschmidtUniversity Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany.ORCID http://orcid.org/0000-0003-0961-0035
Katja C WeiselDepartment of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. k.weisel@uke.de.ORCID http://orcid.org/0000-0001-9422-6614
Universität Hamburg · DEHeidelberg University · DEGerman Cancer Research Center · DEAsklepios Klinik Altona · DECharité - Universitätsmedizin Berlin · DEEssen University Hospital · DEJohannes Gutenberg University Mainz · DEJohanniter-Krankenhaus Bonn · DEKliniken Maria Hilf · DEKlinikum Bielefeld · DEKlinikum Chemnitz · DEKlinikum Osnabrück · DESankt-Antonius-Hospital Eschweiler · DEUniversitätsklinikum Gießen und Marburg · DEUniversity of Tübingen · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneFemaleHumansLenalidomideMaleMiddle AgedMultiple MyelomaOligopeptidesProgression-Free SurvivalAntibodies, Monoclonal, HumanizedcarfilzomibDexamethasoneisatuximabLenalidomideOligopeptides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03104842ClinicalTrials.gov
NCT05558319ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.